This post was originally published on this site
Merck’s drug, molnupiravir, is still under review by regulators in the United States and Europe but was approved for use in the UK last week.
Beximco said it would first launch the generic version – expected to be more affordable – locally in Bangladesh before considering exports depending on regulatory approvals globally.
